Neuropathix, Inc., a pain management life sciences company in Doylestown, has appointed pharmaceutical industry veteran Michael Ropacki, PhD, to its scientific advisory board.

Ropacki is a globally recognized executive with over 20 years’ clinical development experience. Among numerous professional affiliations, he is also a National Institute of Health advisor.

“I am extremely excited and grateful for the opportunity to join the Neuropathix Scientific Advisory Board,” Ropacki stated. “The company’s executive team [comprises] the highest-caliber scientists and executive leadership who are all devoted to developing socially responsible pain management and addiction-related novel therapies.”

He cited the current breadth of the opioid addiction crisis that Neuropathix has called him to help address:

• Over 100 million U.S. citizens struggle with chronic pain
• The domestic costs related to pain management are over $625 billion annually
• Almost two million opioid prescriptions written in the U.S. each year for pain
• Approximately 2.1 million Americans have an opioid-use disorder

“Joining the Neuropathix Scientific Advisory Board is an honor,” Ropacki concluded.

He is eager, he states, to “…help Neuropathix bring novel non-opioid therapeutic agents to market that treat chronic pain and help with opioid withdrawal and addiction.”